[Vaquez disease]

Same author

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Leukemia·2014

Same author

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Leukemia·2013

Same author

Immune aregenerative anemia without erythroblastopenia: a previously undescribed condition.

Annals of hematology·2013

Same author

JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms.

Oncogene·2011

Same author

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.

Leukemia·2010

Same author

Oncogenic mechanisms in myeloproliferative disorders.

Cellular and molecular life sciences : CMLS·2006

Same journal

[Prolonged fever].

La Revue du praticien·2026

Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026

Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026

Same journal

[Patient education in heart failure].

La Revue du praticien·2026

Related Experiment Videos

[Vaquez disease]

Related Concept Videos

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Immune aregenerative anemia without erythroblastopenia: a previously undescribed condition.

JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms.

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.

Oncogenic mechanisms in myeloproliferative disorders.

[Prolonged fever].

[Lower gastrointestinal bleeding].

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

[A history of child abuse intervention in the West].

[Agranulocytose médicamenteuse].

[Patient education in heart failure].

Related Experiment Videos

[Vaquez disease]

Related Concept Videos

Related Articles

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Immune aregenerative anemia without erythroblastopenia: a previously undescribed condition.

JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms.

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.

Oncogenic mechanisms in myeloproliferative disorders.

[Prolonged fever].

[Lower gastrointestinal bleeding].

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

[A history of child abuse intervention in the West].

[Agranulocytose médicamenteuse].

[Patient education in heart failure].